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Abstract
Background—Changes in the multiple mechanisms that regulate glucose metabolism after
gastric bypass (RYGB) are still being unveiled.
Objective—To compare the changes of glucose and pancreatic hormones [C-peptide, glucagon
and pancreatic polypeptide (PP)] during a meal test (MTT) and steady-state insulin and free fatty
acid (FFA) concentrations during euglycemic–hyperinsulinemic clamp 14 days and 6 months after
RYGB in morbidly obese non-diabetic patients.
Setting—Academic Medical Center, United States.
Methods—Two groups were studied at baseline and at 14 days: RYGB followed by caloric
restriction (RYGB, n=12) or equivalent caloric restriction alone (Diet, n=10), to control for energy
intake and weight loss. The RYGB group was studied again at 6 months, to assess the changes
after substantial weight loss. During MTT we determined the early and overall changes in glucose
© 2013 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
Corresponding author: Guilherme M. Campos, MD, FACS, FASMBS., Associate Professor of Surgery. Department of Surgery.
University of Wisconsin School of Medicine and Public Health. 600 Highland Av., K4/730 CSC. Madison, WI 53792-7375., Phone:
(608)263-1036, Fax (608) 265-8810., campos@surgery.wisc.edu.
Author Contributions: G.M.C. obtained funding, designed the study, researched data, wrote the manuscript. C.R. designed the study,
researched data, reviewed/edited the manuscript. P.J.H. researched data, reviewed/edited the manuscript. M.R. designed the study,
researched data, reviewed/edited the manuscript. J.M.S. advised on study design, reviewed/edited the manuscript. M.S. contributed to
study design, researched data, reviewed/edited the manuscript. K.M. contributed to study design, researched data, reviewed/edited the
manuscript.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Surg Obes Relat Dis. Author manuscript; available in PMC 2015 January 01.
Published in final edited form as:
Surg Obes Relat Dis. 2014 ; 10(1): 1–8. doi:10.1016/j.soard.2013.07.010.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and pancreatic hormone concentrations, and during the clamp we assessed steady-state insulin and
FFA concentrations.
Results—After 14 days, RYGB subjects had enhanced post-prandial glucose, C-peptide and
glucagon responses and decreased post-prandial PP concentrations. Steady-state insulin
concentrations were decreased at 14 days only in RYGB subjects, and FFA increased in both
groups. Six months after RYGB and substantial weight loss, the decrease in insulin concentrations
during clamp persisted, and there were further changes in post-prandial glucose and glucagon
responses. FFA concentrations during clamp were significantly lower at 6 months, relative to pre-
surgical values.
Conclusions—RYGB produces, in morbidly obese non-diabetic patients, early changes in post-
meal glucose, C-peptide, glucagon and PP responses, and appears to enhance insulin clearance
early after RYGB and improve insulin sensitivity in adipose tissue at 6 months post-surgery. The
early changes cannot be explained by caloric restriction alone.
Keywords
Gastric bypass; gut hormones; incretins; insulin resistance; free fatty acids; insulin clearance;
hyperinsulinemic euglycemic clamp; bariatric surgery; C-peptide; glucagon; glucose; type 2
diabetes
INTRODUCTION
Roux-en-Y gastric bypass (RYGB) is the most common bariatric surgical procedure used to
treat morbid obesity1 and promotes changes in the regulation of glucose metabolism2. In
addition to improving glucose homeostasis as a consequence of the robust weight loss that
occurs with this procedure, other factors that are likely to contribute to the effects of RYGB
on insulin secretion and action include the magnitude of caloric restriction, reduction in
adipose tissue mass, altered gastrointestinal (GI) and pancreatic hormone responses such as
changes in insulin, glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic
polypeptide (GIP), as well as changes in beta cell function, hepatic glucose metabolism and
bile acids, among others2–4. Although previous studies have reported differences in many of
these parameters after RYGB, the majority of these studies are cross-sectional and few have
controlled for reduced energy intake. In addition, few studies have studied the effects of
surgery on post-prandial glucose kinetics 5,6, glucagon 7 and pancreatic polypeptide (PP)
responses 8, and insulin sensitivity of adipose tissue 9 as assessed by insulin-mediated
suppression of free fatty acids (FFA). Lastly, the potential for changes of hepatic insulin
clearance after RYGB has not been investigated. The current study is a follow-up from
previously published study design, subjects, and other metabolic data10, with additional
analysis of the effects of RYGB on glucose, C-peptide, glucagon, and PP responses during a
meal tolerance test (MTT); and steady state circulating insulin and FFA concentrations
during a euglycemic–hyperinsulinemic clamp. Metabolic studies were done before and 14
days after RYGB followed by caloric restriction or equivalent caloric restriction alone, as
well as 6 months after RYGB.
MATERIAL AND METHODS
Morbidly obese non-diabetic patients, selected to undergo RYGB, were recruited at the
University of California San Francisco’s (UCSF) Bariatric Surgery Program. They met the
National Institutes of Health and UCSF Bariatric Surgery Program eligibility criteria for
bariatric surgery as described previously10. Exclusion criteria included previous weight loss,
foregut and/or hindgut surgery; and diagnosis of endocrine or chronic renal disease. This
project was approved by the UCSF Committee on Human Research and San Francisco
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General Hospital Clinical Research Center (CRC) Advisory Committee. Written consent
was obtained from each participant.
Group Allocation and Metabolic Evaluation
The two groups were studied at baseline and at 14 days: RYGB followed by caloric
restriction (RYGB N=12) or equivalent caloric restriction alone (Diet N=10), to control for
reduced energy intake and weight loss. As previously reported10, the two study groups did
not differ with respect to baseline demographics (Female/Male Ratio: 9:3 RYGB, 6:4 Diet,
p=0.65 and Age in years 47.4±8.7 RYGB, 40.2±13.4 Diet, p=0.16) and body composition
[Weight (kg): 138.0±21.6 RYGB, 134.7±16.9 Diet, p=0.70; BMI (kg/m2): 48.4±6.8 RYGB,
48.3±6.6 Diet, p=0.99 and % Excess body weight: 55.4±6.4 RYGB, 55.3±6.8 Diet, p=0.96),
and participants in both groups were markedly insulin resistant at baseline. The RYGB
group was studied again at 6 months; to assess the longer term changes after more
substantial weight loss had occurred.
All participants underwent the same baseline metabolic evaluation (visit 1, V1)10.
Meal Tolerance Test
On day 1, participants underwent a mixed meal tolerance test (MTT), in which they ingested
a standardized 282 kcal, 100 mL liquid meal containing 50% carbohydrate, 20% protein,
and 30% fat with 9.9 g of simple sugars. Participants consumed this meal within a maximum
of 20 minutes. Venous blood samples were drawn at 0, +5, +15, +30, +60 +120, and +180
minutes relative to the end of the meal. The samples were processed on site and stored at
−70°C for subsequent batch analysis of glucose, C-peptide, glucagon, and PP.
Euglycemic–Hyperinsulinemic Clamp
On day 2, after an overnight fast, whole-body insulin sensitivity and insulin and FFA
concentrations were measured during the steady state interval (60–120 minutes) of a
euglycemic-hyperinsulinemic clamp as described previously 1011. Insulin (Humulin R, Eli
Lilly, Indianapolis, IN, USA), bound to albumin, was administered intravenously at a rate of
40 mU/m2/min for 120 min. Blood was drawn by intravenous catheter in a heated vein, and
whole-blood glucose concentrations were measured in real time at 5-min intervals (YSI
STAT 2300 glucose analyzer, Yellow Springs, OH). Infusion of 20% dextrose was adjusted
to maintain a whole-blood glucose level of 90 mg/dL.
Surgery
The participants assigned to immediate surgery were discharged from the CRC and admitted
for surgery the next day. The RYGB was performed in a standardized fashion by one author
(GC) as previously described 10. In brief, RYGB was performed laparoscopically, a 30-mL
gastric pouch created and connected to an alimentary limb of 100 cm and a biliopancreatic
limb of 50 cm.
Participants were then followed as outpatients for 14 days, during which they consumed a
standardized low calorie diet: Optifast HP (Novartis Nutrition Corporation), which provides
800 kcal/day (25% carbohydrate, 48% protein, and 27% fat).
Follow-up in Patients Undergoing Diet Alone
After completing the baseline evaluation and discharge from the CRC, participants assigned
to the Diet group started the 14-day diet period at home, consuming the identical
standardized diet and with the same follow-up procedures as described for the RYGB group
above. Physical activity was not assessed in either group.
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Follow-up Metabolic Assessments (Visit 2 and Visit 3)
After 14 days of hypocaloric feeding, all participants were readmitted to the CRC (visit 2,
V2) and underwent the same metabolic assessments that were performed at V1. As
previously reported10, after 14 days of caloric restriction with or without RYGB, the
magnitude of weight loss and changes in body composition did not differ significantly
between groups (Weight loss (kg): 9.9±2.4 RYGB, 8.2±2.3 Diet, p=0.11; % Excess weight
loss: 12.7±2.4 RYGB, 10.9±2.8 Diet, p=0.12 and % of weight loss as fat: 40.4±16.2 RYGB,
29.9±16.8 Diet, p=0.22) They were then discharged and continued their standard medical
treatment. Six participants in the Diet group underwent RYGB after the V2 assessment. A
total of 12 participants (nine who were originally assigned to RYGB and three originally
assigned to Diet who subsequently underwent RYGB) had a third inpatient evaluation 6
months after RYGB (visit 3, V3). Six months after undergoing RYGB substantial weight
loss was achieved in all participants (35.7±5.2 kg; EWL=49.7%, p<0.01 vs. V1), of which
72.1% was fat10. The remaining participants in the Diet group went on to have bariatric
surgery and were not studied further.
Laboratory Analyses
Whole-blood and plasma glucose levels were measured by the glucose oxidase method (YSI
2300 STAT-Plus Glucose Analyzer, YSI Inc., Yellow Springs, OH, USA). Serum insulin,
C-peptide and glucagon concentrations were measured by radioimmunoassay (Millipore, St.
Charles, MO, USA). Pancreatic polypeptide concentrations were measured by
radioimmunoassay (Alpco, Salem, NH, USA). Free fatty acid concentrations were measured
by enzymatic assay (Wako Diagnostics, Richmond, VA, USA).
Statistical Analysis
Data are summarized as mean and standard deviation unless otherwise stated. The
unadjusted association of proportions between groups was determined by chi-square test.
Changes in continuous variables from V1 to V2, V1 to V3 and from V2 to V3 were
compared between and within groups using two-sided and paired t tests respectively. The
early changes in glucose and pancreatic hormone concentrations during the MTT were
calculated by linear regression of the estimated slope representing the change (increase or
decrease) of glucose and hormone concentrations between 0 and 15 minutes (Slope 0–15).
To study the overall changes in glucose and hormone concentrations in response to MTT,
we calculated, using the trapezoidal rule, the area under the curve from 0 to 180 minutes
during the MTT (AUC 0–180). In addition, the rate of glucose disappearance from the
bloodstream was calculated by linear regression of the estimated slope representing the
change in glucose from 30 minutes after the start of the meal to the lowest level of glucose
during MTT (glucose disappearance). Average insulin and FFA concentrations during the
steady-state interval (60–120 minutes) of the clamp were calculated. Calculation of excess
weight loss (EWL) used Metropolitan Life Insurance tables to determine ideal weight 12.
Statistical significance was considered to be p<0.05. SPSS, version 13.0.1 (SPSS Inc,
Chicago, IL, USA), was used for all statistical analyses.
RESULTS
Baseline Evaluation (V1)
Prior to surgical and diet interventions, glucose and pancreatic hormone concentrations
during the MTT and insulin and FFA concentrations during the clamp were generally similar
for both groups (Figures 1 and 2), with the exception of C-peptide concentrations, which
were slightly higher in the Diet group.
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Changes at 14 days (RYGB and Diet, V2) and at 6 months (RYGB, V3)
Glucose Concentrations during the MTT—After 14 days, the early increase of plasma
glucose concentrations (Slope 0–15 min) was significantly greater than at baseline in the
RYGB group but not with Diet alone (Figure 1). Similarly, the rate of glucose disappearance
(Slope 30–120 min) was significantly accelerated in the RYGB group (difference in Slope
30–120 between V1 and V2 = −0.26±0.05 mg/dl/min, p=0.02), but remained unchanged in
the Diet group (−0.07±0.05 mg/dl/min, p=0.59). The overall AUC 0–180 for glucose did not
change in either group. Six months after RYGB there was a further increase in the early
change in plasma glucose concentrations (Figure 1) and in glucose disappearance.
Pancreatic Hormone Concentrations During the MTT
C-peptide—After 14 days, the early changes in plasma C-peptide concentrations during
the MTT were significantly greater than at baseline in the RYGB group, whereas changes in
C-peptide concentrations were similar in the Diet group (Figure 1). There were no
significant changes in AUC 0–180 for C-peptide concentrations in either group between
baseline and day 14. There were no further significant changes in C-peptide slopes or AUC
0–180 six months after RYGB (Figure 1).
Glucagon—After 14 days, both the early change and AUC 0–180 for glucagon increased
significantly in the RYGB group, but remained unchanged in the Diet group (Figure 1). Six
months after RYGB, AUC 0–180 for glucagon decreased significantly from responses
measured at 14 days and returned to concentrations similar to those observed at baseline
(Figure 1). In addition, 6 months after RYGB, fasting glucagon concentrations also
decreased significantly from the concentrations measured at 14 days (88.3 pg/mL to 73.9 pg/
mL, p=0.03)
Pancreatic Polypeptide (PP)—Early increases of PP concentrations did not change
significantly in either group at 14 days or 6 months compared with baseline (Figure 1).
However, there was a trend for a decrease in the AUC 0–180 14 days after RYGB
(−19.2±37.2 pmol/L, p=0.14 vs. baseline), and a trend toward an increase in the Diet group
(17.7±24.1, p=0.08 vs. baseline); thus the difference in AUC 0–180 between groups at 14
days was statistically significant (p=0.02). There were no further significant changes of
slopes or the AUC 0–180 for PP, 6 months after RYGB (Figure 1).
Steady-State Insulin and Free Fatty Acid Concentrations During Euglycemic–
Hyperinsulinemic Clamp
After 14 days, the average steady-state insulin concentration during the final hour of the
clamp decreased significantly in the RYGB group, but was unchanged in the Diet group
(Figure 2). The decrease of steady-state insulin concentrations persisted 6 months after
RYGB. FFA concentrations increased significantly and to a similar extent under fasting
conditions and during the clamp in both groups after 14 days. FFA concentrations decreased
significantly 6 months after RYGB (Figure 2).
DISCUSSION
In this study, we observed that RYGB accompanied by caloric restriction was associated
with changes in post-prandial glucose kinetics and concentrations of C-peptide, glucagon,
and PP in response to a meal, as well as changes in steady-state insulin concentrations
during a clamp that were not observed after caloric restriction alone. We also demonstrated
that, after substantial weight loss had occurred, there were further changes of postprandial
glucose kinetics and glucagon responses; and that the augmented postprandial C-peptide
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responses observed at 14 days persisted 6 months after surgery. Lastly, FFA concentrations
were significantly lower at 6 months, relative to pre-surgical and 14-day values.
A major strength of this study is that the metabolic assessments were performed at baseline
and after only 14 days in both groups, while assigned similar diets, to minimize the effects
of different degrees of caloric restriction or weight loss. The follow-up study performed 6
months after RYGB then allowed us to study the effects associated with more substantial
weight loss. Other studies have described the effects of RYGB on glucose homeostasis, but
many of the improvements may also be associated with the profound negative energy
balance and/or weight loss that ensue after surgery13. These considerations are important as
reductions of fasting insulin and glucose concentrations14,15 and hepatic glucose
production16 have been well documented during periods of negative energy balance induced
by hypocaloric feeding and following weight loss17. Our study provides additional evidence
for the presence of unique changes promoted by RYGB that are independent of marked
caloric restriction and modest, but rapid weight loss early after surgery.
The changes of postprandial glucose kinetics we observed after RYGB are in accord with a
cross-sectional study by Rodieux et al.5 that compared non-diabetic, weight-stable women
who had undergone RYGB to those who underwent adjustable gastric banding, and matched
control subjects. Meal-associated glucose kinetics were assessed using labeled glucose.
RYGB subjects showed a more rapid appearance of orally-ingested glucose in the systemic
circulation and a shorter duration of postprandial hyperglycemia than those who had
undergone banding or the unoperated controls. These findings are similar with those
observed in our study, as RYGB subjects had an early post-prandial increase of plasma
glucose followed by an accelerated rate of plasma glucose disappearance after MTT both at
14 days and 6 months. We also reported that, at both 14 days and at 6 months after RYGB,
there was an early increase in the C-peptide responses to meal ingestion; however the
integrated overall response (AUC) was unchanged from baseline concentrations. These
results provide additional evidence that RYGB modify the dynamic of the beta cell secretion
by promoting an earlier and accentuated release of post-prandial C-peptide. In addition, our
data support the hypothesis that these changes occur partly in response the early post-
prandial increase of plasma glucose, as c-peptide and insulin secretion is partly regulated by
the glucose available to the pancreatic beta cell6,18,19.
A novel finding here reportedis the paradoxical increase in post-prandial glucagon responses
at 14 days post-surgery and reduced PP responses in the RYGB group only, changes that
were not sustained 6 months after surgery. This was not an expected finding, as we and
others have reported accentuated post-prandial GLP-1 responses after RYGB, and a known
effect of GLP-1 is inhibition of glucagon secretion 20. Others have reported, though without
a diet control group, an increase of postprandial glucagon excursions early after RYGB21
and a decrease in fasting glucagon concentrations after RYGB and substantial weight loss22,
a finding similar to what was noted in our study. The increase, observed 14 days after
RYGB, likely reflects an inability of glucose to adequately suppress glucagon release after
the meal. It has been suggested that this could be due to “pancreatic type processing” of
proglucagon in the intestinal L-cell with subsequent glucagon release23. The assay used to
measure pancreatic glucagon in this study does not cross-react with oxyntomodulin
(enteroglucagon) which has been reported to increase after RYGB23,24. Another possible
explanation would be an increased activation of the parasympathetic input to the pancreatic
islets, as parasympathetic activation increases glucagon secretion via release of
acetylcholine and neuropeptides such as vasoactive intestinal polypeptide from cholinergic
and peptidergic nerve terminals25. However, this mechanism appears unlikely since PP
responses following the test meal were not increased, but were instead reduced after RYGB.
PP is an islet hormone that is well known to be closely regulated by the activity of the
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parasympathetic input to the islet25. The observation that plasma glucagon responses to
MTT were increased 14 days after RYGB makes suppression of glucagon an unlikely
explanation for the improvement of postprandial glucose metabolism immediately after
surgery. However, fasting glucagon concentrations did decrease progressively with ensuing
weight loss in the months following RYGB in our study and also as has been previously
reported 22, and this could be an additional long-term benefit of RYGB on glucose
metabolism.
An important and interesting finding of our study was that steady-state insulin
concentrations during the clamp, decreased in the RYGB group to a greater extent than in
the Diet group. This result suggests that insulin is cleared more rapidly following RYGB, an
effect that persisted after 6 months. This finding points to the possibility that the liver (as the
central organ regulating glucose storage and production) is likely an important target for the
early improvements of glucose metabolism following RYGB. In addition, studies by others
have demonstrated an association between liver fat and the rate of insulin clearance26 and
that liver fat decreases with RYGB and caloric restriction27. Thus, increased insulin
clearance following RYGB may occur as a result of differential reduction in total liver fat
content after RYGB. This is supported by the observation by others that the liver is
responsible for more than 80% of insulin clearance in the human body and that the main
driver of liver insulin clearance rates is liver fat content26,28,29. A possible, but untested
hypothesis, is a direct effect of the increased postprandial GLP-1 levels on liver fat
content303132.
Lastly, FFA concentrations increased significantly and to a similar extent during the clamp
in both groups at 14 days. The increase of fasting FFA concentrations after 14 days is
consistent with increased fasting lipolysis in individuals in negative energy balance and has
been reported to occur in other studies of the short-term effects of RYGB 22. The higher
FFA concentrations during the clamp could result from either a blunting of the ability of
insulin to suppress lipolysis or decreased FFA clearance (e.g., fat oxidation). At 6 months
after surgery, fasting FFA concentrations returned to baseline levels, likely due to the
subjects being in much less marked negative energy balance. Our study also demonstrated
that FFA concentrations during the clamp were significantly lower after 6 months, relative
to pre-surgical values, suggesting improved insulin sensitivity in adipose tissue at 6 months.
It is important to note that we studied only non-diabetic morbidly obese patients. Diabetic
patients may have worse beta cell function and different hepatic and peripheral dysfunctions
in gluco-regulatory mechanisms and thus likely respond differently to some interventions.
Other limitations of our study include slight but not statistically significant imbalance
between groups in gender distribution, weight loss as fat after 14 days, and possible
differences in diet absorption, that when combined may have impacted the results at 14
days.
CONCLUSIONS
Despite these limitations, we conclude that, in morbidly obese non-diabetics, RYGB is
associated with early and persistent changes in post-prandial glucose kinetics and pancreatic
hormone concentrations. In addition, our data suggest enhanced hepatic insulin clearance
early after RYGB, as well as improved insulin sensitivity in adipose tissue at 6 months.
These findings, taken together with the other documented changes in GI hormones
concentrations, hepatic glucose metabolism, hepatic and peripheral insulin resistance3,4,6,
provide additional evidence that the short and long-term metabolic and endocrine effects of
RYGB, caloric restriction and weight loss have specific and independent effects in the many
organs and tissues that are involved in glycemic control, including the gut, liver, pancreas,
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adipose tissue and muscle; and that these combined effects then contribute to the global
improvements in glucose metabolism following RYGB.
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Figure 1.
Glucose, C-peptide, Glucagon and PP Concentrations after a Meal Tolerance Test at
Baseline, 14 days (RYGB and Diet), and 6 months after (RYGB only).
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Figure 2.
Mean Insulin Concentrations and Free Fatty Acid Concentrations during Euglycemic
Hyperinsulinemic Clamp at Baseline, 14 days (RYGB and Diet), and 6 months after (RYGB
only). (* Marks Clamp procedure start time)
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